5 LGBT things you need to know today, Feb. 21

1. Laws with the biggest impact on LGBT adults have huge effects on kids — for example, a recent study found that after gay marriage was legalized, LGB teen suicide rates began to fall.2. Saudi Arabia is a-...

5 LGBT things you need to know today, Jan. 12

1. A new independent study suggests that younger gay men, aged 18 to 40, are more likely to seek out and maintain monogamous relationships compared to generations past. One possible reason for this is the newly...

5 LGBT things you need to know today, Jan. 5

1. See what Dustin Lance Black — of the Harvey Milk biopic fame — thinks about new movie "Lion," about an Indian boy separated from his birth family and adopted by a couple in Australia, and the parallels it dr...
article placeholder

Increased retention in HIV programs part of new guidelines

Dr. Carlos del Rio

Despite an emphasis on greater HIV testing over the past two decades, an AIDS physicians association is calling for not only more testing, but better follow up to get people who are HIV positive into treatment programs.

On March 5, the International Association of Physicians in AIDS Care (IAPAC) issued a new set of guidelines that challenges how the medical establishment gets people into treatment programs and keeps them enrolled.

“These guidelines are the foundation of an evolving blueprint that practitioners and health systems can use as a resource to improve entry into and retention in HIV care as well as adherence to HIV treatments,” said Dr. Melanie Thompson, co-chair of the IAPAC Panel in a press release issued by IAPAC. Thompson is also Principal Investigator of the AIDS Research Consortium of Atlanta (ARCA).

article placeholder

Tenofovir found safe among gay, bisexual men in new study

A Phase II study of 400 gay and bisexual HIV-negative men who took tenofovir daily through pill form showed no serious safety concerns and could be a resource in the future for the prevention of the spread of the virus, according to researchers.

The study, funded by the Centers for Disease Control & Prevention, was presented at the XVIII International AIDS Conference in Vienna, Austria, on July 23. The study was conducted by the AIDS Research Consortium of Atlanta, the San Francisco Department of Public Health and Fenway Community Health in Boston.

Tenofovir is an oral drug, also known by its brand name Viread. It is used alone or in combination with other antiviral drugs to treat HIV. Tenofovir is not a cure nor is it known for sure if it will prevent the spread of HIV to other people, according to the National Institutes of Health.